— Home
English: EN Français
Partner with us

Patent & IP

Foundational intellectual property.

The SRSF3 platform is supported by a granted U.S. patent and related international filings.

Patent

US 11,530,258 B2

Issued December 20, 2022

Official title

USE OF SRSF3 AGENTS FOR THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL CONDITIONS, CANCER, BACTERIAL INFECTIONS OR VIRAL INFECTIONS

What it covers

  • Methods of treating specified neurological conditions — including ALS, frontotemporal lobar degeneration (FTD), Alzheimer’s disease, Parkinson’s disease and vascular dementia, among others listed in the claims — by administering an SRSF3 agent to a patient.
  • The claimed SRSF3 agents are antibodies or antisense/RNA-interference agents that inhibit the expression or function of SRSF3.
  • Dependent claims address antisense oligonucleotides directed to the 5′ region of human SRSF3 mRNA (including morpholino chemistry) and antibody formats.

Plain-language summary. The claims of the issued patent define its actual scope.

Inventors
Jasna Kriz · Hejer Boutej
Assignee
Université Laval (Québec, Canada)
Application
U.S. Appl. No. 16/763,906
PCT application
PCT/CA2018/051452 (filed November 15, 2018)
Priority
U.S. provisional 62/586,567 — November 15, 2017
Claims
15
View on Google Patents (opens in a new tab) USPTO Patent Public Search (opens in a new tab)

Patent

Patent family

As listed on the public record for WO 2019/095064. Status may change.

JurisdictionNumberStatus
United StatesUS 11,530,258 B2Granted
Europe (EPO)EP 3710015 B1Granted
CanadaCA 3095354 A1Published application
ChinaCN 111556761 APublished application
JapanJP 2021502977 APublished application
PCT (WIPO)WO 2019/095064 A1International publication

Patent & IP

Relationship to RNOVA Tx

The RNOVA Tx scientific platform is supported by foundational SRSF3 intellectual property originating from the laboratory of Dr. Jasna Kriz at Université Laval. The patent’s named inventors, Dr. Jasna Kriz and Dr. Hejer Boutej, are the co-founders of RNOVA Tx. Details of the commercial rights arrangement will be communicated once finalized.

Advancing a new paradigm in CNS immunotherapy.

RNOVA Tx welcomes conversations with pharmaceutical, biotechnology, scientific and development partners interested in RNA therapeutics and neurodegenerative disease.

Partner with RNOVA rnovatx@gmail.com